Melanoma biology and new targeted therapy (Q36742015)

16 August 2017

1 reference

title

Melanoma biology and new targeted therapy (English)

1 reference

16 August 2017

Richard Marais

3

0 references

Claudia Wellbrock

object named as

Claudia Wellbrock

series ordinal

2

0 references

author name string

Vanessa Gray-Schopfer

series ordinal

1

1 reference

PubMed ID

17314971

16 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

16 August 2017

7

1 reference

inferred from page(s)

published in

Nature

1 reference

16 August 2017

445

1 reference

16 August 2017

851-857

1 reference

16 August 2017

7130

1 reference

https://scigraph.springernature.com/pub.10.1038/nature05661

16 August 2017

0 references

cites work

Melanin pigmentation in mammalian skin and its hormonal regulation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Molecular basis of congenital hypopigmentary disorders in humans: a review

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Cutaneous Malignant Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

The role of altered cell-cell communication in melanoma progression

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

https://api.crossref.org/works/10.1038%2FNATURE05661

1 reference

7 January 2021

A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Updated statistical data for malignant melanoma in Japan

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

The pathogenesis of melanoma induced by ultraviolet radiation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Distinct sets of genetic alterations in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

The RAF proteins take centre stage

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Metastasizing Melanoma Formation Caused by Expression of Activated N-RasQ61Kon an INK4a-Deficient Background

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Essential role for oncogenic Ras in tumour maintenance

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

The role of B-RAF in melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

The Brn-2 transcription factor links activated BRAF to melanoma proliferation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Cellular senescence in naevi and immortalisation in melanoma: a role for p16?

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

BRAFE600-associated senescence-like cell cycle arrest of human naevi

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Ras, PI(3)K and mTOR signalling controls tumour cell growth

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Mutations of PIK3CA are rare in cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

PTEN signaling pathways in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Deregulated Akt3 activity promotes development of malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

V599EB-RAF is an oncogene in melanocytes

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

MITF: master regulator of melanocyte development and melanoma oncogene

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Genetic and epigenetic alterations of the APC gene in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Human melanocyte senescence and melanoma susceptibility genes

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Genetics of melanoma predisposition

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

The INK4a/ARF locus and melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

High frequency of BRAF mutations in nevi

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Mutational analysis of N-ras, p53, CDKN2A (p16(INK4a)), p14(ARF), CDK4, and MC1R genes in human dysplastic melanocytic naevi

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Apoptosis and melanoma chemoresistance

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Cutaneous melanoma: available therapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Chemotherapy and targeted therapy combinations in advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase cascade is regulated by IkappaB kinase-induced proteolysis of NF-kappaB1 p105.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Therapeutic targets: MTOR and related pathways

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

The role of Bcl-2 family members in the progression of cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Inhibitors of the HSP90 molecular chaperone: current status

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Integrins: molecular targets in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

The evolving portrait of cancer metastasis.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNATURE05661

7 January 2021

Identifiers

DOI

10.1038/NATURE05661

1 reference

16 August 2017

1 reference

PubMed ID

17314971